Macquarie Group’s Structure Therapeutics GPCR Stock Holding History

Macquarie Group’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-58,000	Closed	-$1.62M	–	1111
2025 Q3	$1.62M	Hold	58,000	–	–	﹤0.01%	1232
2025 Q2	$1.2M	Hold	58,000	–	–	﹤0.01%	1338
2025 Q1	$1M	Hold	58,000	–	–	﹤0.01%	1384
2024 Q4	$1.57M	Hold	58,000	–	–	﹤0.01%	1261
2024 Q3	$2.55M	Hold	58,000	–	–	﹤0.01%	1157
2024 Q2	$2.28M	Hold	58,000	–	–	﹤0.01%	1189
2024 Q1	$2.49M	Buy	+58,000	New	+$2.45M	﹤0.01%	1159

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Macquarie Group's GPCR Position: Q4 2025 in Review

Macquarie Group sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 58,000 shares — an estimated $1.62M sold.

Macquarie Group first reported a position in GPCR in Q1 2024 and held it in 7 quarters. The position peaked at $2.55M in Q3 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

Macquarie Group reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 58,000 Structure Therapeutics shares in Q4 2025, an estimated $1.62M.
Macquarie Group first reported a position in Structure Therapeutics in Q1 2024 and held it in 7 quarters.
Macquarie Group's Structure Therapeutics position peaked at $2.55M in Q3 2024.
197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.